Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-Current Debt: 2013-2024

Historic Non-Current Debt for Ocular Therapeutix (OCUL) over the last 12 years, with Dec 2024 value amounting to $68.5 million.

  • Ocular Therapeutix's Non-Current Debt rose 4.13% to $70.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.6 million, marking a year-over-year increase of 4.13%. This contributed to the annual value of $68.5 million for FY2024, which is 4.13% up from last year.
  • Per Ocular Therapeutix's latest filing, its Non-Current Debt stood at $68.5 million for FY2024, which was up 4.13% from $65.8 million recorded in FY2023.
  • Ocular Therapeutix's Non-Current Debt's 5-year high stood at $68.5 million during FY2024, with a 5-year trough of $16.9 million in FY2020.
  • Moreover, its 3-year median value for Non-Current Debt was $65.8 million (2023), whereas its average is $53.2 million.
  • Per our database at Business Quant, Ocular Therapeutix's Non-Current Debt tumbled by 32.27% in 2020 and then skyrocketed by 160.47% in 2023.
  • Yearly analysis of 5 years shows Ocular Therapeutix's Non-Current Debt stood at $16.9 million in 2020, then soared by 47.61% to $25.0 million in 2021, then grew by 1.03% to $25.3 million in 2022, then skyrocketed by 160.47% to $65.8 million in 2023, then climbed by 4.13% to $68.5 million in 2024.